LuPIN data published today makes it likely, in my opinion, that Novartis will WANT to do a deal with Noxopharm.
Median survival for all 56 end-stage prostate patients was 19.7 months, a significant improvement over the 17.1 months reported for the low-dose patients. It is actually better than it sounds.
LuPIN patients were more resistant to treatment than those enrolled in the VISION registration trial being conducted by Endocyte/Novartis, having had to have failed more prior therapies. VISION is expected to achieve median survival of about 13.5 months, based on results from a trial that enrolled 50 similar patients. It is remarkable that the addition of Veyonda was able to extend median survival by 6 months, to 19.7 months, in harder-to-treat patients.
LuPIN abstract, page-7
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.014(14.6%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 9.2¢ | 11.5¢ | 9.2¢ | $53.30K | 518.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 48681 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 74195 | 4 |
View Market Depth
| Last trade - 15.45pm 23/08/2024 (20 minute delay) ? |
| NOX (ASX) Chart |